Boehringer Ingelheim Boosts COVID-19 Efforts As Jardiance Continues To Impress
Paid Leave For Volunteering For All Employees
Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.
You may also be interested in...
Mereo BioPharma’s completed private placement in the US will support clinical studies of its candidate immuno-oncology product etigilimab and a later-stage anti-sclerotin antibody product with potential in the treatment of brittle bone disease.
Novartis will not start to compete in the increasingly crowded US multiple sclerosis marketplace with ofatumumab this month, as regulators extend the review process for the B-cell depleting therapy until September.
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.